Monte Rosa Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| GLUE | CCCC | KYMR | ARVN | NRIX | OLMA | |
|---|---|---|---|---|---|---|
| Market cap | 897.50M | 376.46M | 9.22B | 480.68M | 2.30B | 643.98M |
| P/E (TTM) | — | — | — | 28.7 | — | — |
| Forward P/E | -5.4 | -3.2 | -22.0 | -2.3 | -20.8 | -2.8 |
| Price/book | 1.8 | 1.5 | 6.1 | 0.9 | 5.7 | 1.5 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −0.96% | +49.76% | +87.68% | −20.83% | +129.94% | −27.26% |
| Today | +2.14% | −3.16% | −0.28% | −2.49% | −0.85% | −5.88% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All GLUE news ›Investment Analysts’ Weekly Ratings Changes for Monte Rosa Therapeutics (GLUE)
Posted by Michael Walen on Oct 10th, 2026 Several brokerages have updated their recommendations and price targets on shares of Monte Rosa Therapeutics (NASDAQ: GLUE) in the last few weeks: Monte Rosa’s pipeline is centered primarily on…
Monte Rosa Therapeutics officer sells 13 shares
Monte Rosa Therapeutics (GLUE) is a clinical-stage biotech developing molecular glue degrader medicines for oncology, autoimmune, inflammatory and cardiovascular diseases. - [Form 4] Monte Rosa Therapeutics, Inc. Insider Trading Activity…
Monte Rosa Therapeutics, Inc. (GLUE) Discusses GFORCE-1 Phase I Results for NEK7 Molecular Glue Degrader MRT-8102 in Cardiovascular Disease Risk - Slideshow
(NASDAQ:GLUE) 2026-10-05 Seeking Alpha The following slide deck was published by Monte Rosa Therapeutics, Inc. in conjunction with this event.
Monte Rosa's MRT-8102 Shows Biomarker Gains in GFORCE-1 Study
Monte Rosa Therapeutics NASDAQ: GLUE reported results from GFORCE-1, a Phase I study of its NEK7-directed molecular glue degrader MRT-8102 in participants with elevated cardiovascular risk. The company said the four-week dosing study…
Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Rating Raised to “Strong-Buy” at HC Wainwright
Posted by Mitch Edgeman on Oct 2nd, 2026 Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) was upgraded by equities researchers at HC Wainwright to a “strong-buy” rating in a research report issued to clients and investors on…
Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price Down 6% – Here’s Why
Posted by Tristan Rich on Oct 1st, 2026 Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE – Get Free Report)’s share price fell 6% during mid-day trading on Thursday. The stock traded as low as $11.16 and last traded at $11.2190. Approximately…
Monte Rosa’s MRT-8102 shows NLRP3 inflammasome activity normalization in Phase 1 study
The Clinical Trial Vanguard Monte Rosa’s MRT-8102 shows NLRP3 inflammasome activity normalization in Phase 1 study Monte Rosa Therapeutics reported Phase 1 data on October 1 that investors in the NLRP3 inflammasome space had been waiting…
Monte Rosa Therapeutics to present Phase 1 MRT-8102 data in CVD risk subjects
tradersunion.com Monte Rosa Therapeutics to present Phase 1 MRT-8102 data in CVD risk subjects Monte Rosa Therapeutics announced plans to present results from GFORCE-1, its Phase 1 study of MRT-8102 in subjects with elevated cardiovascular…
Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk
investingnews.com Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company…
Monte Rosa posts trial data for anti-inflammatory drug (GLUE)
Seeking Alpha Monte Rosa Therapeutics (GLUE) traded higher in premarket after the company announced plans to begin multiple Phase 2 trials for its anti-inflammatory agent MRT-8102 following encouraging results from a Phase 1 study. The…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
themarketsdaily.com3
-
marketbeat.com2
-
seekingalpha.com2
-
stocktitan.net1
-
tradersunion.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 9 articles, not a forecast.